Navigation Links
ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
Date:11/2/2009

MINNEAPOLIS, Nov. 2 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced the first human robot assisted endoscopic aortic valve replacement using the daVinci® Surgical System from Intuitive Surgical (Nasdaq: ISRG) to implant the ATS 3f® Aortic Bioprosthesis. The procedure was performed by Allen Raczkowski, M.D., at Banner Baywood Health Hospital in Phoenix, Arizona.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

"The ATS 3f Aortic Bioprosthesis is the only valve that has the extreme flexibility necessary for small access robotic ports and it provides excellent hemodynamic characteristics which are important for the patient's quality of life," said Dr. Raczkowski.

With the recent introduction of the ATS 3f Aortic Bioprosthesis into the U.S. marketplace, surgeons have quickly recognized its unique potential for use in less invasive port access and robot assisted procedures. Because the ATS 3f valve is the first truly stentless valve in the world, it has no rigid supporting stent. As a result, the valve is completely pliable which allows it to be folded into a small diameter and introduced to the body through small ports using minimally invasive techniques. No other commercially available valve can be manipulated in this manner. This successful first ever minimally invasive human aortic valve replacement is the result of an ongoing cooperative effort with many of the leading robot experienced cardiac surgery centers in the U.S. to develop minimally invasive aortic valve procedures.

"ATS Medical has been committed from the beginning to the development of minimally invasive solutions for the treatment of structural heart disease. The ability to remove and replace a diseased heart valve in a minimally invasive manner represents a dramatic benefit for patients for two reasons: better clinical outcomes by removing the diseased valve as opposed to leaving it in place, and secondly, a much more cosmetically favorable procedure versus the pain and scaring associated with conventional open chest surgery. This landmark robot assisted endoscopic aortic replacement procedure by Dr. Raczkowski is another important step toward providing surgeons and patients better options for the treatment of structural heart disease without an open sternotomy," stated Michael Dale, President and CEO of ATS Medical.

This procedure establishes the expansion of the Company's minimally invasive initiatives to the 3f product line in addition to the ongoing efforts with the ATS CryoMaze® Surgical System and the ATS Simulus® family of annuloplasty products. ATS has also created the position of "Business Development Manager of Minimally Invasive Procedures" to focus increased resources on the development of procedures and products to drive adoption, expand markets, and provide less traumatic surgical options for patients.

About ATS Medical

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot® Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f® brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f® portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus® annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Electronic Medical Record System and More
2. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
3. Nonin Medical Recognized for Influential Contributions in Medical Technology
4. Burton Medicals New Diagnostic Examination Light, the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life
5. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
6. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
7. Stryker Biotech and its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries
8. Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation
9. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
10. Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes
11. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):